Intellia Therapeutics Inc (NTLA) Expected to Announce Quarterly Sales of $12.73 Million

Share on StockTwits

Wall Street brokerages expect Intellia Therapeutics Inc (NASDAQ:NTLA) to announce $12.73 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Intellia Therapeutics’ earnings, with the lowest sales estimate coming in at $7.12 million and the highest estimate coming in at $25.40 million. Intellia Therapeutics reported sales of $7.32 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 73.9%. The business is expected to report its next earnings report on Tuesday, October 30th.

According to Zacks, analysts expect that Intellia Therapeutics will report full-year sales of $41.09 million for the current fiscal year, with estimates ranging from $29.59 million to $58.40 million. For the next fiscal year, analysts forecast that the company will post sales of $43.64 million per share, with estimates ranging from $25.56 million to $58.30 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Wednesday, August 1st. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.03. Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The firm had revenue of $7.68 million for the quarter, compared to the consensus estimate of $6.39 million. During the same quarter in the previous year, the firm earned ($0.45) earnings per share. The company’s quarterly revenue was up 30.2% compared to the same quarter last year.

NTLA has been the topic of several recent analyst reports. Cann reissued a “hold” rating on shares of Intellia Therapeutics in a research note on Tuesday, May 1st. TheStreet downgraded shares of Intellia Therapeutics from a “c-” rating to a “d” rating in a research note on Monday, May 7th. Chardan Capital raised shares of Intellia Therapeutics from a “neutral” rating to a “buy” rating in a research note on Tuesday, May 15th. BidaskClub raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 16th. Finally, Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Intellia Therapeutics in a research note on Friday, May 18th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $34.14.

In other Intellia Therapeutics news, insider John M. Leonard sold 8,400 shares of the stock in a transaction dated Monday, May 14th. The shares were sold at an average price of $24.00, for a total transaction of $201,600.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jean Francois Formela sold 6,686 shares of the stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $31.17, for a total transaction of $208,402.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,458 shares of company stock worth $764,361. Company insiders own 12.80% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN boosted its holdings in shares of Intellia Therapeutics by 108.0% in the 4th quarter. Wells Fargo & Company MN now owns 34,767 shares of the company’s stock valued at $668,000 after buying an additional 18,050 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Intellia Therapeutics by 1.9% in the 4th quarter. BlackRock Inc. now owns 1,710,947 shares of the company’s stock valued at $32,885,000 after buying an additional 31,662 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Intellia Therapeutics by 42.5% in the 4th quarter. Geode Capital Management LLC now owns 195,925 shares of the company’s stock valued at $3,765,000 after buying an additional 58,411 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of Intellia Therapeutics by 8.5% in the 4th quarter. Deutsche Bank AG now owns 41,744 shares of the company’s stock valued at $800,000 after buying an additional 3,279 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Intellia Therapeutics by 306.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 129,900 shares of the company’s stock valued at $2,497,000 after buying an additional 97,936 shares in the last quarter. Institutional investors own 59.81% of the company’s stock.

Intellia Therapeutics traded up $0.18, reaching $27.67, during mid-day trading on Tuesday, Marketbeat.com reports. 404,637 shares of the company’s stock traded hands, compared to its average volume of 665,178. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -14.72 and a beta of 2.93. Intellia Therapeutics has a 12-month low of $15.06 and a 12-month high of $35.99.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Featured Story: Market Capitalization

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply